Boston Scientific Corporation BSX
Boston Scientific is a buy at $46.84 following the post-cyberattack selloff, trading at 18.89x trailing P/E — approximately 29% below the peer median of 26.66x — despite FY2025 revenue of $20.07B (up 19.87% YoY) and diluted EPS of $1.94 (up 55.2% YoY). A cluster buy by four insiders including CEO Michael Mahoney deploying approximately $9.5M between July 31 and August 25, 2026 signals management confidence even as a cybersecurity incident causes ongoing global operational disruption.
With FY2025 free cash flow of $3.658B and an FCF margin of 18.22%, the fundamental franchise remains intact while the stock sits well below its 200-day moving average of $68.145, pricing in significant worst-case scenarios.
What could go wrong
- Cyberattack impact escalation. The August 26, 2026 cybersecurity incident is causing global disruption to order processing and shipping; the company has stated the nature, scope, and impact are yet to be determined, meaning Q3 2026 results could be materially affected.
- Product recall compounding disruption. The same August 26 news cycle referenced a product recall alongside the cyberattack, adding a second layer of near-term operational and reputational risk.
- Technical breakdown. Stock at $46.84 is well below the 200-day MA of $68.145 with a negative MACD histogram of -0.589 and RSI at 43.0, indicating persistent downward momentum that could attract further selling.
- Institutional outflows. Smart money score is slightly negative at -0.0191 as of the quarter ended 2026-06-30, with fund count declining from 71 to 68 quarter-over-quarter, suggesting modest institutional caution predating the cyberattack.
What would change my mind
Where this comes from: FMP FY2025 annual + derived_metrics · peer_relative composite · insider cluster_buy · news articles (TechCrunch, CNBC, Motley Fool, Benzinga). Orin's read on BSX; not advice.
Twelve months actual closes to 2026-09-23 · actual filings
50-day average 200-day average · volume below
On file
All BSX filingsLargest holders · 13F Q2 2026
Money flow| Filer | Position | Of fund |
|---|---|---|
| Vanguard Capital Management | $4.1B | 0.1% of fund |
| State Street | $3.0B | 0.1% of fund |
| Brasada Capital Management | $2.6B | 0.5% of fund |
| Fmr | $2.0B | 0.1% of fund |
| Massachusetts Financial Services /Ma/ | $1.5B | 0.5% of fund |
| Geode Capital Management | $1.4B | 0.1% of fund |
121 filers · quarter ended Q2 2026 · positions, not flows
Insiders, last 24 months: 281 Form 4 filings, net −$88.3M. Of the 50 on hand, 6 were open-market purchases and 0 sales— the rest are grants, option exercises and tax withholding.
Ask Orin about BSX
Orin answers questions about BSX from its filings, transcripts and numbers — with the source behind every claim. Your own desk starts with 3 free days, card required.
Start 3 free days →Where it trades
| Metric | Now | Own median | Sector |
|---|---|---|---|
| P/E | 18.0× | 58.1× | 26.4× |
| EV/EBITDA | 13.8× | 27.2× | — |
| P/S | 3.16× | 5.90× | — |
| P/B | 2.6× | 4.4× | — |
Its P/E sits below all 5 of the last 5 years (−2.83σ from its own mean).
6.4%
free-cash-flow growth every year for 10 years, discounted at 10%, is what today’s price implies — starting from $3.7B of trailing free cash flow. It is an assumption the market is making, not a forecast Orin is making.
What Wall Street published
$65
$50 – $100 · +46% against today's price
- 37 buy or overweight
- 7 hold
- 0 underweight or sell
The analysts’ consensus and their own ratings, not Orin’s. A target is a twelve-month opinion published by the firm that wrote it.
Against the companies it is compared to
| Company | Market cap | P/E | EV/EBITDA | Gross | Net | ROE |
|---|---|---|---|---|---|---|
| BSXBoston Scientific Corporation | $66B | 18.0× | 13.8× | 71.2% | 17.5% | 15% |
| ABTAbbott Laboratories | $179B | 33.3× | 20.8× | 56.8% | 11.6% | 11% |
| AMGNAmgen Inc. | $219B | 25.0× | 15.9× | 72.7% | 22.9% | 89% |
| DHRDanaher Corporation | $156B | 39.2× | 24.9× | 58.5% | 15.9% | 8% |
| GILDGilead Sciences, Inc. | $188B | — | 331.4× | 79.6% | -10.6% | -16% |
| HCAHCA Healthcare, Inc. | $94B | 14.6× | 9.0× | 28.4% | 8.8% | -113% |
| MCKMcKesson Corporation | $103B | 23.5× | 15.3× | 3.6% | 1.1% | -194% |
| MDTMedtronic plc | $114B | 21.8× | 14.9× | 66.7% | 13.9% | 11% |
| PFEPfizer Inc. | $161B | 37.2× | 17.6× | 71.3% | 6.8% | 5% |
| SYKStryker Corporation | $105B | 28.1× | 18.6× | 65.2% | 14.4% | 16% |
The median is of the 8 peers listed above and nothing else — check it against the column. This company trades 32.3% below it. The peer set is the vendor’s, so a company can appear here that a person would not have chosen.
What it has traded at
What its sector has traded at
Two scales, drawn separately on purpose: a sector median and one company’s multiple are not the same number and putting them on one axis invites a comparison neither series supports.
Discounted cash flow
| Model | Fair value | Against | Computed |
|---|---|---|---|
| Standard DCF | $94 | $48.26 · +96% | 2026-06-10 |
| Levered DCF | $110 | $48.26 · +129% | 2026-06-10 |
The vendor’s intrinsic-value models. Treat them as a low-growth anchor — for a fast grower the market routinely pays well above a DCF. These were computed against the price in the “against” column, not today’s.
Every estimate on one scale
The vertical rule is the current price. Ranges and point estimates are the backend’s, published as they were calculated; an arrow means the estimate sits beyond this scale, and its number is on the right.